Abstract

Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care

Trials.2022 Jul 8;23(1):552. doi: 10.1186/s13063-022-06492-6.

 

Sarah L Alderson 1Alexandra Wright-Hughes 2Alexander C Ford 3 4Amanda Farrin 2Suzanne Hartley 2Catherine Fernandez 2Christopher Taylor 2Pei Loo Ow 2Emma Teasdale 5Daniel Howdon 6Elspeth Guthrie 6Robbie Foy 6Matthew J Ridd 7Felicity L Bishop 5Delia Muir 2Matthew Chaddock 8Amy Herbert 7Deborah Cooper 6Ruth Gibbins 9Sonia Newman 9Heather Cook 10Roberta Longo 6Hazel Everitt 9

 
     

Author information

1School of Medicine, Leeds Institute of Health Sciences, University of Leeds, University of Leeds, Room 10.39, Worsley Building, Clarendon Way, Leeds, LS9 9LU, UK. s.l.alderson@leeds.ac.uk.

2Clinical Trial Research Unit, Leeds Institute of Clinical Trials Research, School of Medicine, University of Leeds, Leeds, UK.

3Leeds Gastroenterology Institute, St James's University Hospital, Leeds, UK.

4Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.

5Centre for Clinical and Community Applications of Health Psychology, School of Psychology, University of Southampton, Southampton, UK.

6School of Medicine, Leeds Institute of Health Sciences, University of Leeds, University of Leeds, Room 10.39, Worsley Building, Clarendon Way, Leeds, LS9 9LU, UK.

7Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

8Let's Cure IBS, Sheffield, UK.

9Primary Care Research Centre, Faculty of Medicine, University of Southampton, Southampton, UK.

10Exeter Clinical Trials Unit, University of Exeter, Exeter, UK.

Abstract

Background: Irritable bowel syndrome (IBS) is a common functional bowel disorder that has a considerable impact on patient quality of life and substantial societal and health care resource costs. Current treatments are often ineffective. Tricyclic antidepressants have shown promise in secondary care populations but their effectiveness in a primary care setting remains unclear.

Methods: ATLANTIS is a randomised, multi-centre, parallel-group, two-arm, double-blind, placebo-controlled trial of low-dose amitriptyline as a second-line treatment for IBS in primary care. Participants will be invited by letter, or recruited opportunistically, from general practices in three regions of England (West Yorkshire, Wessex, and West of England) and screened for eligibility. A total of 518 adult patients with IBS, who are symptomatic despite first-line therapies, will be randomised 1:1 to amitriptyline or identical placebo for 6 months. Treatment will commence at a dose of 10 mg (or one placebo tablet) daily at night, with dose titration up to a maximum of 30 mg at night, depending on side effects and response to treatment. Participant-reported assessments will be conducted at baseline and 3, 6, and 12 months post-randomisation. The primary objective is to determine the effectiveness of amitriptyline, compared with placebo, in improving participant-reported global symptoms of IBS at 6 months (using the IBS Severity Scoring System). Secondary outcomes include relief of IBS symptoms, effect on IBS-associated somatic symptoms (Patient Health Questionnaire-12), anxiety and depression (Hospital Anxiety and Depression Scale), ability to work and participate in other activities (Work and Social Adjustment Scale), acceptability and tolerability of treatment, self-reported health care use, health-related quality of life (EQ-5D-3L), and cost-effectiveness. A nested, qualitative study will explore patient and general practitioner experiences of treatments and trial participation, including acceptability, adherence, unanticipated effects, and implications for wider use of amitriptyline for IBS in primary care.

Discussion: Determining the clinical and cost-effectiveness of low-dose amitriptyline as a second-line treatment for IBS in primary care will provide robust evidence to inform management decisions.

Trial registration: ISRCTN ISRCTN48075063 . Registered on 7th June 2019.

 

 

© Copyright 2013-2022 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.